A study including 11 NSCLC cell lines investigated the preclinical efficacy of MK-5108, a strong inhibitor of AURKA that had shown a potent preclinical activity in malignancies of breast, cervical, colon, ovarian, and pancreatic origin (53). The gene discussed is AURKA; the disease is non-small cell lung carcinoma.